Articles From: Arotech Corporation Reports Record Revenues for its Results of the Fourth Quarter and Full Year 2012 to Array BioPharma To Present At The Leerink Swann Global Healthcare Conference


2013/3/18
Record Q4 revenue up 23% year-over-year ANN ARBOR, Mich.
Sign-up for Arotech Corporation Reports Record Revenues for its Results of the Fourth Quarter and Full Year 2012 investment picks
2013/5/13
Revenues up 37% over same period last year; net profit of $0.4 million ANN ARBOR, Mich.
Sign-up for Arotech Corporation Reports Results For The First Quarter, 2013 investment picks
2013/5/2
ANN ARBOR, Mich.
Sign-up for Arotech Receives $4.0 Million In New Awards For Training And Simulation Products investment picks
2013/5/20
ANN ARBOR, Michigan , May 20, 2013 /PRNewswire/ -- Arotech Corporation (Nasdaq GM: ARTX) announced today that Steven Esses , President of Arotech, will be presenting the Company later today at the 14th Annual B.
Sign-up for Arotech's President to Present Today at B. Riley Investor Conference investment picks
2013/2/19
- Division backlog at over $70 million ANN ARBOR, Mich.
Sign-up for Arotech's Training and Simulation Division Starts 2013 With $4.5 Million in New Awards investment picks
2013/4/1
ArQule, Inc. (NASDAQ: ARQL) today announced it has regained worldwide rights for the development and commercialization of compounds covered under its AKT collaboration with Daiichi Sankyo Co., Ltd., including the lead compound emerging from this collaboration, ARQ 092.
Sign-up for ArQule Regains Worldwide Rights to AKT Program investment picks
2013/5/8
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the first quarter of 2013.
Sign-up for ArQule Reports First Quarter 2013 Financial Results investment picks
2013/3/14
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the year and for the fourth quarter ended December 31, 2012.
Sign-up for ArQule Reports Fiscal 2012 Year End and Fourth Quarter Results investment picks
2013/5/1
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the first quarter of 2013 on Wednesday, May 8, 2013 at 7:00 a.m. Eastern Time.
Sign-up for ArQule to Report First Quarter 2013 Financial Results on May 8, 2013 investment picks
2013/3/7
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the fiscal 2012 year-end and fourth quarter on Thursday, March 14, 2013 at 7:00 a.m. eastern time.
Sign-up for ArQule to Report Fiscal 2012 Financial Results on March 14, 2013 investment picks
2013/2/27
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Cowen and Company 33 rd Annual Health Care Conference on Wednesday, March 6, 2013 at 8:00 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com .
Sign-up for ArQule, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference investment picks
2013/5/30
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Jefferies 2013 Global Healthcare Conference on Thursday, June 6, 2013 at 11:00 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com .
Sign-up for ArQule, Inc. to Present at Jefferies 2013 Global Healthcare Conference investment picks
2013/2/7
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Leerink Swann Global Healthcare Conference on Thursday, February 14, 2013 at 1:30 p.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com .
Sign-up for ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference investment picks
2013/4/23
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Needham 12 th Annual Healthcare Conference on Tuesday, April 30, 2013 at 10:40 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com .
Sign-up for ArQule, Inc. to Present at Needham 12th Annual Healthcare Conference investment picks
2013/2/19
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2013 RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at 10:00 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com .
Sign-up for ArQule, Inc. to Present at RBC Capital Markets Global Healthcare Conference investment picks
2013/4/9
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. (NASDAQ: ARQL) at the AACR (American Association for Cancer Research) Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
Sign-up for ArQule’s Novel AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase 1 Trial investment picks
2013/5/6
-Targets difficult-to-treat patient population with few remaining options - - MEK162 also expected to advance into Phase 3 studies in NRAS and BRAF melanoma in 2013- BOULDER, Colo.
Sign-up for Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer investment picks
2013/5/15
BOULDER, Colo.
Sign-up for Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting investment picks
2013/6/4
BOULDER, Colo.
Sign-up for Array BioPharma Announces Pricing of Public Offering of $115 Million of Convertible Senior Notes investment picks
2013/6/3
BOULDER, Colo.
Sign-up for Array BioPharma Announces Proposed Public Offering of Convertible Debt investment picks
2013/3/21
Hematology / oncology industry expert to lead promising development pipeline BOULDER, Colo.
Sign-up for Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer investment picks
2013/2/4
MEK162 Phase 3 Trial to Start April 2013 AstraZeneca Announced Selumetinib Potential Phase 3 NSCLC Trial Start in 2013 BOULDER, Colo.
Sign-up for Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013 investment picks
2013/5/6
Array MEK162 Phase 3 Trial Announced in Ovarian Cancer AstraZeneca Announced Registration Trials with Selumetinib in NSCLC and Thyroid Cancer in 2013 Array Reaffirms Financial Guidance for the Fiscal Year BOULDER, Colo.
Sign-up for Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013 investment picks
2013/2/26
BOULDER, Colo.
Sign-up for Array BioPharma To Present At The Cowen Annual Health Care Conference investment picks
2013/5/30
BOULDER, Colo.
Sign-up for Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference investment picks
2013/2/8
BOULDER, Colo.
Sign-up for Array BioPharma To Present At The Leerink Swann Global Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Arotech Corporation Reports Record Revenues for its Results of the Fourth Quarter and Full Year 2012 to Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity